Anti-interferon alpha antibodies and autoantibodies in patients with Beh double dagger et's disease uveitis treated with recombinant human interferon alpha-2a

---

Copy For Citation

Aydinoglu-Candan O., Araz-Ersan B., Gül A., Badur S., Tugal-Tutkun I.

GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, vol.253, no.3, pp.457-465, 2015 (SCI-Expanded)

• Publication Type: Article / Article
• Volume: 253 Issue: 3
• Publication Date: 2015
• Doi Number: 10.1007/s00417-014-2856-3
• Journal Name: GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Page Numbers: pp.457-465
• Keywords: Behcet's disease, Interferon, Anti-interferon alpha antibody, Binding antibody, Autoantibody, CHRONIC HEPATITIS-C, LONG-TERM EFFICACY, BEHCETS-DISEASE, MULTIPLE-SCLEROSIS, AUTOIMMUNE-DISEASE, NEUTRALIZING ANTIBODIES, BETA ANTIBODIES, THERAPY, SAFETY, PANUVEITIS
• Istanbul University Affiliated: Yes

Abstract

Recombinant human (rh) interferon alpha2a (IFN-alpha 2a) therapy is successfully used for the treatment of Beh double dagger et's disease (BD) uveitis refractory to conventional immunosuppressive treatment.